Login
Companies $MREO
$0.30 -$0.00 (0.85%) After hours
Mereo BioPharma Group plc logo

Mereo BioPharma Group plc

mereobiopharma.com

What Do They Do?

Develops rare-disease drug candidates, including setrusumab and alvelestat, for pharmaceutical and biotechnology partners.

How Do They Make Money?

Mereo licenses drug-candidate rights to pharmaceutical and biotechnology partners and can receive upfront fees, research and development payments, milestone payments, and royalties on product sales. Upfront license fees are paid when the partner receives the license; milestone payments depend on reaching agreed development, regulatory, or sales goals.

FY2025 revenue

Who Are Their Customers?

Pharmaceutical and biotechnology companies take licenses or collaborate directly with Mereo on drug candidates, with rights covering worldwide or specified territories.

Do Revenues Turn Into Profits?

No. It lost $41.9M in FY2025.

Operating income, FY2025
−8021% of revenue
▲ +15% (Loss) vs FY2024 (−$47.4M)
Net income, FY2025
−8376% of revenue
▲ +3% (Loss) vs FY2024 (−$43.3M)
Free cash flow, FY2025
−6198% of revenue
▲ +6% (Loss) vs FY2024 (−$32.8M)

How Are They Changing?

Since the FY2025 annual report
Latest quarter: Q3 FY2026, the three months to Sep 30, 2026
Revenue
vs $0 in Q3 FY2025
Net income
▲ +17% (Loss)
vs −$7M in Q3 FY2025
  • Aug 18, 2026 Nasdaq extended Mereo's deadline to meet its minimum bid-price rule The notice did not immediately affect listing; failure to regain compliance by the extended period could lead to delisting.
  • Aug 11, 2026 Sentynl received an option to license alvelestat in the United States If exercised, Sentynl can sell alvelestat in the United States and manufacture it globally; Mereo leads the Phase 3 trial and keeps sales rights elsewhere.

A tighter rare-disease focus The older report described oncology candidates alongside rare-disease programs; the latest report frames the core pipeline around rare diseases, while etigilimab remains available for partnering.

Leflutrozole partnership Leflutrozole moved from a candidate Mereo planned to partner or sell to a global license with ReproNovo, which holds worldwide rights and is responsible for future development and commercialization.

Who Do They Compete With?

Competes with Amgen, UCB, Transcenta Holding, Eli Lilly and, BOOST Pharma, Angitia Biopharmaceuticals, Grifols, Shire, Takeda Pharmaceutical, CSL, Kamada, Sanofi, Wave Life Sciences, Beam Therapeutics, Krystal Biotech, Korro Bio, Roche, Merck, iTeos, and GSK

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Premium Feature

This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.

Premium includes:

  • Unlimited historical financial data
  • Advanced analytics and insights
  • Priority support